



UNIVERSITI PUTRA MALAYSIA

MECHANISMS OF ANTITUMOUR ACTIVITY OF 3, 19-(2-BROMOBENZYLIDENE) ANDROGRAPHOLIDE (SRJ09)

LIM SIANG HUI

FPSK(M) 2007 14



IMPORTANT

The following manuscript " **MECHANISMS OF ANTITUMOUR ACTIVITY OF 3,19-(2-BROMOBENZYLIDENE)ANDROGRAPHOLIDE (SRJ09)**" is submitted to the School of Graduate Studies, Universiti Putra Malaysia, in fulfillment of the requirements for the Degree of Master of Science by Lim Siang Hui. This manuscript can only be used for personal viewing and no part of this manuscript may be reprinted, linked to, or otherwise redistributed, in any form or by any means, without first obtaining the prior written consent of the author.

If you wish to reprint or reproduce this work, or if you have any enquiries, please email **Lim Siang Hui** (limsianghui@hotmail.com)



**MECHANISMS OF ANTITUMOUR ACTIVITY OF
3,19-(2-BROMOBENZYLIDENE)ANDROGRAPHOLIDE (SRJ09)**

By

LIM SIANG HUI

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia,
in Fulfilment of the Requirements for the Degree of Master of Science
September 2007**



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment of the requirement for the degree of Master of Science

**MECHANISMS OF ANTITUMOUR ACTIVITY OF
3,19-(2-BROMOBENZYLIDENE)ANDROGRAPHOLIDE (SRJ09)**

By

LIM SIANG HUI

September 2007

Chairman: Associate Professor Johnson Stanslas, PhD

Faculty: Medicine and Health Sciences

To date, most of the clinical cytotoxic anticancer drugs target all rapidly dividing cells and are non-selective in their mechanism of action by disrupting essential components that are crucial to both malignant and normal cells. Hence, the search for more effective and selective anticancer drugs is currently being researched actively involving the various entities of the drug discovery programme. We at UPM have shown that andrographolide (AGP), a compound isolated from a local herb, *Andrographis paniculata*, to have anticancer activity *in vitro* and *in vivo*. In order to improve the antitumour properties of AGP, semi-synthetic derivatives of this compound were synthesised in our laboratory, with the aim of identifying the most promising anticancer compound among the AGP derivatives and to elucidate the mechanism(s) of action of the compound. The *in vitro* antitumour study showed that 3,19-(2-bromobenzylidene)andrographolide (SR09) displayed better antitumour activity when compared with AGP and other derivatives namely 3,19-(2-chlorobenzylidene)andrographolide (SRJ11) and 3,19-(3-chloro-4-fluorobenzylidene) andrographolide (SRJ23). The antitumour activity of AGP, SRJ09, SRJ11 and SRJ23 was shown to be not compromised by P-glycoprotein activities in MES-SA Dx5 multidrug resistant cell line. The time-course study

revealed SRJ09 had a rapid acting interval compared with AGP. SRJ09 was previously shown to induce G1-phase cell cycle arrest and in this study the effect was shown attributed to increased of p21 (CDK inhibitor) expression without affecting the expression of cyclin D1. Apoptosis was the main mode of cell death induced by SRJ09 and was p53 and bcl-2 independent, which might suggest that SRJ09 act through the extrinsic apoptotic pathway. A simple pharmacokinetic study was performed in Balb/c for the purpose of dose selection for *in vivo* study revealed that SRJ09 had a relatively short half-life but was able to reach *in vitro* cytotoxic concentration range. In a subsequent *in vivo* antitumour study, SRJ09 delayed quadruple tumour growth by 4 day in HCT-116 colon cancer xenografted mice treated with 400 mg/kg SRJ09 (q4d×3) when compared with control. In conclusion, SRJ09 have been proven as a lead anticancer agent given to its ability to induce *in vitro* cell cycle arrest and apoptosis and to have *in vivo* antitumour activity. Therefore, further studies in improving the anticancer properties of SRJ09 by chemical modification will be advantageous.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia
sebagai memenuhi keperluan untuk ijazah Master Sains

**MEKANISME AKTIVITI ANTIKANSER
3,19-(2-BROMOBENZILEDINE)ANDROGRAPHOLIDE (SRJ09)**

Oleh

LIM SIANG HUI

September 2007

Pengerusi: Profesor Madya Johnson Stanslas, PhD

Fakulti: Perubatan dan Sains Kesihatan

Sehingga kini, kebanyakan agen antikanser klinikal bertindak ke atas sel yang membahagi dengan cepat dan mempunyai mekanisme yang tidak selektif dengan mengganggu komponen asas yang penting untuk kedua-dua sel kanser dan sel normal. Oleh yang demikian, penemuan agen antikanser yang lebih efektif dan selektif kini dikaji dengan aktif dengan melibatkan pelbagai entiti program penemuan ubatan. Kajian kami di UPM menunjukkan bahawa andrographolide (AGP), sebatian yang dipencil dari *Andrographis paniculata*, mempunyai aktiviti antikanser secara *in vitro* and *in vivo*. Untuk meningkatkan potensi antitumor AGP, terbitan semisintetik sebatian ini disintesis di makmal kami, bertujuan untuk mengenalpasti sebatian antikanser yang poten di antara terbitan AGP dan seterusnya memahami mekanisme tindakannya. Secara *in vitro*, 3,19-(2-bromobenzyldiene)andrographolide (SRJ09) menunjukkan kelebihan aktiviti antikanser berbanding dengan AGP dan terbitan yang lain seperti 3,19-(2-chlorobenzyldiene)andrographolide (SRJ11) dan 3,19-(3-chloro-4-fluorobenzyldiene)andrographolide (SRJ23). Aktiviti antikanser AGP, SRJ09, SRJ11 dan SRJ23 didapati tidak dipengaruhi oleh aktiviti P-glikoprotein sel MES-SA Dx5 yang resistan terhadap pelbagai agen antikanser. Kajian berlandaskan masa

menunjukkan SRJ09 mempunyai sela masa tindakan yang pantas berbanding dengan AGP. Kajian terdahulu menunjukkan bahawa SRJ09 merencat kitaran sel pada fasa G1 dan dalam kajian ini, kesan ini didapati berpunca dari peningkatan ekspresi p21 (perencat kinase bergantung siklin) dan tidak mempengaruhi ekspresi siklin D1. Kajian yang selanjutnya menunjukkan bahawa apoptosis merupakan punca utama kematian sel yang diaruh oleh SRJ09 dan adalah bebas daripada regulasi p53 dan Bcl-2. Untuk tujuan penentuan dos kajian *in vivo*, kajian farmakokinetik ringkas ke atas mencit Balb/c menunjukkan bahawa SRJ09 mempunyai separuh hayat yang pendek tetapi mampu mencapai julat konsentrasi sitotoksik *in vitro*. Dalam kajian *in vivo*, SRJ09 melewati pertumbuhan tumor kepada empat kali ganda selama empat hari dalam mencit yang ditenokan dengan kolon kanser HCT-116 yang dirawat dengan 400 mg/kg SRJ09 (q4d×3) berbanding dengan kawalan. Kesimpulannya, SRJ09 dikenalpasti sebagai agen antikanser pilihan utama kerana kebolehannya untuk merencat kitaran sel dan mengaruh apoptosis secara *in vitro* serta menunjukkan aktiviti antikanser secara *in vivo*. Justeru itu, kajian lanjutan untuk memperbaiki aktiviti antikansernya melalui modifikasi kimia adalah bermanfaat.

ACKNOWLEDGEMENTS

During the course of my graduate study, many individuals have generously contributed their time and support in making the completion of this project possible. I would like to take this opportunity to extend my sincere gratitude to those who had provided guidance in every step of the way. Without them, I will not have achieved my success today.

First and foremost, I would like to acknowledge my excellent supervisor, Associate Professor Dr Johnson Stanslas, for his persistent direction and constructive guidance throughout my study. I would also like to heartily thank him for spending his precious time in reading and correcting this thesis. It has been a real pleasure and a positive learning experience working in your laboratory as a graduate student. As demanding as these years has been, they were equally enjoyable and unforgettable.

My appreciation is also extended to Prof Dr Zaayah Yusuf and Dr Nazil Salleh for their valuable advice and guidance throughout the course of this project.

A very special appreciation is extended to all the members of CRDD, especially Audrey, Sagi, Tang, Guru, Velan, Viknes, Jebril and Wijayahadi for being there as a friend, a labmate and for providing many wonderful time and memories which I will treasured forever. In addition, my appreciation is also sincerely extended to Hamzani, Rijalana, and staffs of IMR (especially Mala and Zul) for their continuous help during my research work.

I would also like to thank my family especially my parents for their constant and loving support over the years. I am forever grateful.

Lastly, I would like to extend my deepest gratitude to Hoon Koon for always being there and understanding and believing in everything that I do. Her relentless support and devoted companionship during the course of my study are also greatly appreciated.

I certify that an Examination Committee met on 19th September 2007 to conduct the final examination of Lim Siang Hui on his Master of Science thesis entitled “Mechanisms of Antitumour Activity of 3,19-(2-bromobenzylidene)andrographolide (SRJ09), a Semisynthetic Derivative of Andrographolide” in accordance with Universiti Pertanian Malaysia (Higher Degree) Act 1980 and Universiti Pertanian Malaysia (Higher Degree) Regulations 1981. The Committee recommends that the candidate be awarded the relevant degree. Members of the Examination Committee are as follows:

Muhammad Nazrul Hakim Abdullah, PhD

Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Chairman)

Asmah Rahmat, PhD

Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Internal Examiner)

Mohamad Aziz Dollah, PhD

Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Internal Examiner)

Mohd Zaini Asmawi, PhD

Professor
School of Pharmaceutical Sciences
Universiti Sains Malaysia
(External Examiner)

Hasanah Mohd Ghazali, PhD

Professor/ Deputy Dean
School of Graduate Studies
Universiti Putra Malaysia

Date:

This was thesis submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of Master of Science. The members of the Supervisory Committee were as follows:

Johnson Stanslas, PhD

Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Chairman)

Mohammad Nazil Salleh, PhD

Lecturer
School of Life Sciences
Technology Park Malaysia Academy
(Member)

Zauiyah Yusuf, PhD

Professor
Department of Medical Microbiology and Immunology
Universiti Kebangsaan Malaysia
(Member)

AINI IDERIS, PhD

Professor and Dean
School of Graduate Studies
Universiti Putra Malaysia

Date: 22 January 2008

DECLARATION

I hereby declare that the thesis is based on my original work except for quotations and citations which have been duly acknowledged. I also declare that it has not been previously or concurrently submitted for any other degree at UPM or other institutions.

LIM SIANG HUI

Date:

TABLE OF CONTENTS

	Page
ABSTRACT	ii
ABSTRAK	iv
ACKNOWLEDGEMENTS	vi
APPROVAL	viii
DECLARATION	x
LIST OF TABLES	xiv
LIST OF FIGURES	xv
LIST OF ABBREVIATIONS	xviii
 CHAPTER	
 1 INTRODUCTION	 1
1.1 Overview	1
1.2 Objectives	3
 2 LITERATURE REVIEWS	 4
2.1 Cancer Biology And Development	4
2.1.1 Self-sufficiency in Growth Signals	6
2.1.2 Insensitivity to Antigrowth Signals	7
2.1.3 Evading Apoptosis	8
2.1.4 Limitless Replicative Potential	9
2.1.5 Sustained Angiogenesis	10
2.1.6 Tissue Invasion and Metastasis	11
2.2 Modalities of Anticancer Treatment	12
2.2.1 Chemotherapy	13
2.2.1.1 Alkylating Agents	14
2.2.1.2 Antimetabolites	15
2.2.1.3 Anthracyclines	17
2.2.1.4 Antimicrotubule Agents	19
2.2.1.5 Topoisomerase Inhibitors	21
2.2.1.6 Hormonal Agents	23
2.3 Cell Death Pathways As Chemotherapeutic Targets	24
2.3.1 Apoptosis	25
2.3.1.1 The Intrinsic Pathway	27
2.3.1.2 The Extrinsic Pathway	28
2.3.2 Necrosis	29
2.4 Andrographolide	32
 3 MATERIALS AND METHODS	 37
3.1 Materials	37
3.1.1 Cell Lines	37
3.1.2 Reagents and Chemicals	37
3.1.3 Antibodies and Protein Ladder	38
3.1.4 Laboratories Wares	39
3.1.5 Instrumentations	39
3.2 Methods	40



3.2.1	Preparation of Drugs	40
3.2.2	Cell Culture	40
3.2.3	Cryogenic Preservation and Recovery	41
3.2.4	Microculture MTT (Tetrazolium) Assay	42
3.2.5	Stability Study	43
3.2.5.1	Sample Collection and Extraction	43
3.2.5.2	High Performance Liquid Chromatography (HPLC)	44
3.2.6	Cell Morphological Study Using DNA Fluorochromes	45
3.2.7	DNA Fragmentation Analysis	47
3.2.8	Western Blotting	48
3.2.8.1	Isolation of Total Proteins from Cancer Cells	48
3.2.8.2	SDS-PAGE Electrophoresis	49
3.2.8.3	Semi-Dry Western Blotting and Immunodetection	50
3.2.8.4	Stripping and Reprobing Membranes	51
3.2.9	Pharmacokinetic Study	52
3.2.9.1	Dosing of Animal with Vehicle and Compound	52
3.2.9.2	Sample Collection and Handling	52
3.2.9.3	Extraction Procedure	53
3.2.9.4	HPLC Analysis	53
3.2.10	<i>In Vivo</i> Chemotherapeutic Study	54
3.2.10.1	Animals and Environmental Control	54
3.2.10.2	Development of Human Tumour Xenografts in Nude Mice	55
3.2.10.3	<i>In Vivo Antitumoural Assay</i>	56
3.2.11	<i>Statistical Analysis</i>	57
4	<i>IN VITRO</i> ANTITUMOUR PROPERTIES OF NEW DERIVATIVES AGP	58
4.1	Introduction	58
4.2	Results and Discussion	60
4.2.1	Growth Inhibitory Effects of AGP and Its Derivatives	60
4.2.2	AGP and SRJ09 Exposure Interval Effects on Cell Growth Inhibition	65
4.2.3	Effect of AGP, SRJ09 and SRJ11 against Multidrug Resistant Cell Line	69
4.2.4	Stability of AGP and SRJ09 in Complete Culture Medium	73
4.3	Summary	77

5	REGULATION OF CELL CYCLE ARREST AND CELL DEATH BY SRJ09	78
5.1	Introduction	78
5.2	Results and Discussion	79
5.2.1	Identification of The Mode(s) of Cell Death Induced by SRJ09	79
5.2.2	DNA Fragmentation Induced by SRJ09 on HCT-116	85
5.2.3	Effects of SRJ09 on p53, Bcl-2, Cyclin D1 and p21 Protein Expression in MCF-7 and HCT-116 cells	86
5.3	Summary	95
6	<i>IN VIVO</i> ANTITUMOUR PROPERTIES OF SRJ09	97
6.1	Introduction	97
6.2	Results and Discussion	98
6.2.1	Pharmacokinetics of SRJ09 in Balb/C Mice	98
6.2.2	Effects of SRJ09 on HCT-116 Xenografted Nude Mice	102
6.3	Summary	107
7	GENERAL DISCUSSION AND CONCLUSION	108
7.1	General Discussion	108
7.2	Conclusion	110
7.3	Recommendation of Future Research	111
	REFERENCES	113
	APPENDICES	123
	BIODATA OF THE AUTHOR	129

LIST OF TABLES

Table		Page
2.1	Morphological changes and biochemical features between apoptosis and necrosis	25
3.1	Dilutions of antibodies	51
3.2	Pharmacokinetic parameters calculation	54
4.1	GI ₅₀ values (in μM) of AGP, SRJ09, SRJ11, SRJ23 and DOX against a panel of cancer cell lines	61
4.2	TGI values (in μM) of AGP, SRJ09, SRJ11, SRJ23 and DOX against a panel of cancer cell lines	62
4.3	LC ₅₀ values (in μM) of AGP, SRJ09, SRJ11, SRJ23 and DOX against a panel of cancer cell lines	63
4.4	GI ₅₀ , TGI and LC ₅₀ values (in μM) of AGP, SRJ09, SRJ11, SRJ23 and DOX in HUVEC cell line	64
4.5	Growth inhibitory parameters of AGP and SRJ09 at different exposure intervals against MCF-7 cell line	67
4.6	Growth inhibitory parameters of AGP and SRJ09 at different exposure intervals against HCT-116 cell line	69
4.7	Growth inhibitory parameters of AGP, SRJ09 and SRJ11 against human sarcoma cell line MES-SA and its multidrug resistant sublines MES-SA/Dx5	72
6.1	Pharmacokinetic parameters obtained after single i.p bolus administration of 100 mg/kg SRJ09	99
6.2	The % T/C values of SRJ09 treatment at various doses on each measurement day	104

LIST OF FIGURES

Figure		Page
2.1	Acquired capabilities that sustained cancer development	5
2.2	Chemical structure of cyclophosphamide	15
2.3	Deoxythymidine synthesis pathway as antimetabolites target	16
2.4	Chemical structures of methotrexate and 5-fluorourasil	17
2.5	Chemical structures of doxorubicin and daunorubicin	18
2.6	Chemical structures of vinca alkaloids and taxane	20
2.7	Chemical structures of topoisomerase I inhibitor and topoisomerase II inhibitor	23
2.8	Apoptosis through the extrinsic and intrinsic pathway	26
2.9	The induction of necrosis caused by the inhibition of cellular energy production, imbalance of intracellular calcium flux, generation of ROS, and activation of non-apoptotic proteases	32
2.10	Chemical structure of AGP	33
2.11	Chemical structures of semisynthetic derivatives of AGP	35
3.1	Three endpoints parameter of GI_{50} , TGI and LC_{50} as determined from a dose-response growth curves	43
4.1	NCI Self-Organize Maps (SOM) of AGP and its derivatives into similar pattern of growth inhibition to standard agents with known molecular target	59
4.2	Representative dose-response curves of time interval exposure effect of AGP and SRJ09 against MCF-7 cell growth	66
4.3	Representative dose-response curves of time intervals exposure effect of AGP and SRJ09 on HCT-116 cell growth	68
4.4	Representative dose-response curves of growth inhibitory effects of AGP, SRJ09, SRJ11 and DOX against MES-SA and MES-SA Dx5 cells	71
4.5	Stability of AGP and SRJ09 in RPMI 1640 culture medium	74
4.6	Structures of camptothecin and lovastatin and their respective hydroxyl acid form	75

4.7	Proposed hydrolysis of andrographolide lactone form to hydroxyl acid form	76
4.8	Dose-response curves of growth inhibitory effects of freshly prepared (0 hr) and 24 hr pre-incubated SRJ09 against MCF-7 cells	77
5.1	Fluorescence micrographs (400X) of HCT-116 cells after AO/PI staining	80
5.2	Induction of apoptosis and necrosis by SRJ09 in MCF-7 cells at various concentration and time points	81
5.3	Induction of apoptosis and necrosis by SRJ09 in HCT-116 cells at various concentration and time points	83
5.4	Fluorescence micrographs of untreated control and SRJ09-treated HCT-116	84
5.5	DNA fragmentation in HCT-116 cells treated with SRJ09 for 24 hr	86
5.6	Western blot analysis of p53 apoptotic regulatory protein in SRJ09-treated MCF-7 cells	87
5.7	Western blot analysis of bcl-2 apoptotic regulatory protein in SRJ09-treated MCF-7 cells	88
5.8	Western blot analysis of cyclin D1 cell cycle regulatory protein in SRJ09-treated MCF-7 cells	89
5.9	Western blot analysis of p21 cell cycle regulatory protein in SRJ09-treated MCF-7 cells	90
5.10	Western blot analysis of p53 apoptotic regulatory protein in SRJ09-treated MCF-7 cells	91
5.11	Western blot analysis of bcl-2 apoptotic regulatory protein in SRJ09-treated MCF-7 cells	92
5.12	Western blot analysis of cyclin D1 cell cycle regulatory protein in SRJ09-treated MCF-7 cells	93
5.13	Western blot analysis of p21 cell cycle regulatory protein in SRJ09-treated MCF-7 cells	94
6.1	SRJ09 plasma concentration-time profile in mice following single i.p bolus administration of 100 mg/kg SRJ09	99

6.2	Logarithm of SRJ09 plasma concentration-time profile in mice following single i.p bolus administration of 100 mg/kg SRJ09	100
6.3	Growth of HCT-116 tumour xenografts in nude mice	103
6.4	A comparative effect of SRJ09 treatment on tumour volume in HCT-116 xenografted nude mice with the vehicle control	105
6.5	Percentage of relative body weight of mice receiving various SRJ09 doses	106

LIST OF ABBREVIATIONS

ADP	adenosine diphosphate
AGP	andrographolide
AIF	apoptosis-inducing factor
AO	acridine orange
APAF	apoptotic protease activating factor-1
ATP	adenosine triphosphate
AUC	area under curve
bp	base pair
C ₀	initial concentration
Ca ²⁺	calcium ion
CDK	cyclin dependent kinase
Cl	clearance
C _{max}	maximum concentration
CO ₂	carbon dioxide
DD	death domain
DISC	death-inducing signalling complex
DMSO	dimethylsulfoxide
DNA	deoxyribonucleic acid
DNase	deoxyribonuclease
DOX	doxorubicin
DR	death receptors
dTMP	2'-deoxythymidine-5'-phosphate
dUMP	2'-deoxyuridine-5'-phosphate
ECGS	endothelial cell growth supplement

EDTA	ethylenediaminetetraacetic acid
EGF	epidermal growth factor
FADD	Fas-associated death domain
FasL	Fas ligand
FBS	feotal bovine serum
FGF	fibroblast growth factors
Fig	figure
GI ₅₀	50% growth inhibition concentration
HCl	hydrochloride acid
HPLC	high performance liquid chromatography
HRP	horse radish peroxidase
HUVEC	human umbilical vein endothelial cell
i.p.	intraperitoneum
IGF	insulin-like growth factor
IgG	immunoglobulin type-G
K _{el}	elimination rate constant
LC ₅₀	50% lethal concentration
MAPK	mitogen-activated protein kinase
MDR	multidrug resistance
MgCl ₂	magnesium chloride
MTT	3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
NaCl	sodium chloride
NAD	nicotinamide adenine dinucleotide
NCI	National Cancer Institute
PAGE	polyacrylamide gel electrophoresis

PARP	poly(ADP-ribose) polymerase
PBS	phosphate buffered saline
PBS-T	PBS containing 0.1% Tween 20
PDGF	platelet-derived growth factor
PI	propidium iodide
RIP	receptor-interacting protein
RNA	ribonucleic acid
RNase	ribonuclease
ROS	reactive oxidative species
RR	resistant ratio
RTV	relative tumour volume
SD	standard deviation
SDS	sodium dodecyl sulphate
SEM	standard error mean
Smac	second mitochondria-derived activator of caspases
SOM	self-organise maps
T _½	half-life
TEMED	N,N,N',N'-tetramethylethylenediamine
TGF	tumour growth factor
TGI	total growth inhibition
T _{max}	time to achieved C _{max}
TNF	tumour necrosis factor
TNFR	tumour necrosis factor receptor
TRAIL	tumour necrosis factor-related apoptosis inducing ligand
UV	ultraviolet

V	volt
V_d	volume of distribution
VEGF	vascular endothelial growth factor
w/v	weight over volume

CHAPTER 1

INTRODUCTION

1.3 Overview

Cancer is a new growth of tissue in which cell multiplication is uncontrolled and progressive. Unlike benign tumour cells, cancer cells exhibit the properties of invasion and metastasis and are highly anaplastic. In 2002, it is reported that cancer is the second major cause of death, which account 12.5% of total deaths worldwide (The World Health Report 2003). Surgical excision, radiation therapy and chemotherapy are the main approaches to treat cancer. Unlike surgery and radiation therapy, chemotherapy is considered a systemic treatment in which the drugs circulate in the blood circulations to eradicate cancer micrometastases at distant sites from the original cancer. Therefore, chemotherapy is often administered in conjunction with local therapy such as surgery and radiation to obtained optimal effects. The use of anticancer drugs as part of the treatment strategy for cancer has greatly improved the overall prognosis of cancer patients.

To date, most of the anticancer drugs target all rapidly dividing cells and are non-selective in their mechanism of action by disrupting essential components or metabolic pathways that are crucial to both malignant and normal cells (Ewesuedo and Ratain 2003). Therefore, scientists are still looking for more effective and type-selective antitumour drugs with minimum side effects. Several strategies were employed which include chemical modification or combinatorial chemistry involving

existing natural and synthetic products, structure-based drug design and new natural products discovery. The search for new natural products from the vast biodiversity is an importance source of structural diversity that yield unusual and unexpected lead structures which served as starting points for chemical modification to derive an optimal drug (Young 1999).

In the early 2000, andrographolide (AGP) a compound isolated from *Andrographis paniculata* received much attention as a candidate to be developed into anticancer agents. AGP was shown to inhibit tumour growth both *in vitro* and *in vivo* (Stanslas et al. 2001; Rajagopal et al. 2003). AGP was also reported to cause G₁ phase cell cycle arrest (Stanslas et al. 2001; Rajagopal et al. 2003) and apoptosis (Cheung et al. 2005; Kim et al. 2005; Zhou et al. 2006). Shortly, AGP was derivatised through various chemical modifications in an effort to improve its antitumour potential (Nanduri et al. 2004; Jada et al. 2006). The derivatives synthesised by coupling of two hydroxyl groups in AGP (C-3 and C-19) by reacting AGP with benzaldehydes having different functional groups are generally shown to have an improvement in terms of antitumour activity (Jada et al. 2006). Hence, in this study several lead derivatives were selected and evaluated, in order to identify the most potent anticancer compound among AGP derivatives and their mechanism(s) of action.